Harmony Biosciences Gets FDA Orphan Designation for Pitolisant in Prader-Willi Syndrome
By Colin Kellaher
Harmony Biosciences Holdings has won orphan-drug designation from the U.S. Food and Drug Administration for its pitolisant drug candidate for the treatment of the genetic disorder Prader-Willi syndrome.
The Plymouth Meeting, Pa., pharmaceutical company said it plans to assess the safety and efficacy of pitolisant in treating excessive daytime sleepiness and behavioral disturbances in patients with Prader-Willi in a Phase 3 registrational study slated to launch during the first quarter.
The FDA's orphan-drug program gives special status to drugs and biologics for diseases and disorders that affect fewer than 200,000 people in the U.S. and provides for an extended marketing exclusivity period against competition.
Harmony said 15,000 to 20,000 people in the U.S. are living with Prader-Willi, a rare neurological disorder with symptoms that result from dysfunction of the part of the brain that controls sleep-wake state stability and signals that mediate the balance between hunger and satiety.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
February 20, 2024 08:34 ET (13:34 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
What’s Happening in the Markets This Week
-
Worst-Performing Stock ETFs of the Quarter
-
Q3 in Review and Q4 2024 Market Outlook
-
Top-Performing Stock ETFs of the Quarter
-
September Jobs Report Forecasts Show Moderate Hiring Gains
-
Port Strike a Headache for Shippers but a Potential Tailwind for Certain US Transport Stocks
-
13 Charts on Q3′s Roller-Coaster Rally for Stocks and Bonds
-
5 Stocks to Buy Instead of Overpriced US Equities
-
Consumer Defensives: Despite Angst, Thirsty Investors Have Names to Pursue
-
Industrials: Many Stocks Overvalued After Q3 Outperformance
-
Basic Materials: Despite Index Rise, We See Multiple Long-Term Opportunities
-
What the Election Could Mean for Big Tech Stocks
-
3 Lessons From Recent Stock Market Drama
-
Consumer Cyclicals: Even Amid Moderating Consumer Spending, We See Discounts
-
Healthcare: Valuations Look Fair Overall, With Select Industries Still Undervalued
-
Utilities: Falling Interest Rates, Growth Outlook Boosting Stocks